The funding round included new investors Schroders Capital, 3B Future Health Fund, Caribou Property, and British Patient Capital. Existing investors Epidarex Capital and ALSA Ventures have also participated
Co-led by Canaan Partners and Red Tree Venture Capital, the financing round included significant investment from Johnson & Johnson Innovation – JJDC. SV Health Investors and Novo Holdings
Daprodustat is an investigational oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) that is indicated to treat anaemia of CKD in adult patients not on dialysis and on dialysis.
The regulatory agency issued a complete response letter (CRL) to the company’s New Drug Application (NDA) for lenacapavir mentioning Chemistry Manufacturing and Controls (CMC) issues related to its
Jointly developed and commercialised by Pharmacyclics, Imbruvica (ibrutinib) is a once-daily oral medication that blocks the Bruton’s tyrosine kinase (BTK) protein. The sNDA seeks approval for the drug
Keytruda is Merck’s an anti-programmed death receptor-1 (PD-1) therapy that increases the ability of the immune system in body for detecting and fighting tumour cells. It is a
The investigational, phosphodiesterase 4B (PDE4B) inhibitor, BI 1015550 has the potential to address pulmonary fibrosis as well as inflammation linked to progressive fibrosing interstitial lung diseases (ILDs). Pulmonary
INNA-051 is a broad spectrum antiviral immunomodulatory nasal spray, which is under clinical development to treat pre- and post-exposure prophylaxis of respiratory viral infections in people at risk
Cariprazine is intended for the adjunctive treatment of MDD patients who are receiving ongoing antidepressant therapy. The company’s sNDA submission is based on data obtained from clinical trials
Utidelone Injection, developed by Beijing Biostar Pharmaceuticals, is a new natural microbial small-molecule anticancer drug that is a genetically engineered epothilone derivative. It is a new non- taxane
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.